High Dose Chemotherapy for Hodgkin's Disease
Author Information
Author(s): G.B. Zulian, P. Selby, S. Milan, A. Nandi, M. Gore, G. Forgeson, T.J. Perren, T.J. McElwain
Primary Institution: The Institute of Cancer Research and The Royal Marsden Hospital
Hypothesis
Can high dose melphalan, BCNU, and etoposide with autologous bone marrow transplantation effectively treat relapsed Hodgkin's disease?
Conclusion
The treatment is effective against relapsed Hodgkin's disease but must be used cautiously due to significant risks of lung toxicity.
Supporting Evidence
- 76% of patients responded to the treatment.
- 53% achieved complete remission.
- 45% of patients were free of disease at follow-up.
- 26% of patients experienced treatment-related deaths.
Takeaway
Doctors gave strong medicine to 38 people with a type of cancer called Hodgkin's disease to help them get better, but some got very sick from the treatment.
Methodology
Patients received a combination of high dose melphalan, BCNU, and etoposide followed by autologous bone marrow transplantation.
Potential Biases
Potential bias due to the lack of randomization and selection of patients.
Limitations
The study lacked a control group and had case selection bias.
Participant Demographics
38 patients, 23 male and 15 female, aged 15 to 51 with a median age of 28.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website